Mylenda Injection 0.25 mg/0.5 ml contains Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used in the management of type 2 diabetes mellitus. Semaglutide is designed to improve glycemic control by targeting multiple pathways involved in glucose regulation, making it an effective and well-established option for patients who require injectable antidiabetic therapy.

Semaglutide works by mimicking the action of the natural GLP-1 hormone. It enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying. These combined effects help lower both fasting and postprandial blood glucose levels while reducing the risk of hypoglycemia when used alone. Additionally, semaglutide acts on appetite centers in the brain, often leading to reduced food intake and gradual weight loss, which is beneficial for many patients with type 2 diabetes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Mylenda Injection is indicated as an adjunct to diet and exercise for:

• Management of type 2 diabetes mellitus in adults

• Improvement of glycemic control when oral antidiabetic agents are insufficient

• Patients requiring a once-weekly GLP-1 receptor agonist therapy

It may be used as monotherapy or in combination with other antidiabetic medications as prescribed by a healthcare professional.

Dosage and Administration

Mylenda Injection is administered by subcutaneous injection. The 0.25 mg dose is typically used as a starting dose to help patients adjust to the medication and reduce gastrointestinal side effects. Dose escalation should be done gradually, based on clinical response and tolerability, as directed by a physician.

The injection can be given in the abdomen, thigh, or upper arm. It should be administered on the same day each week, with or without meals. Proper injection technique and rotation of injection sites are recommended.

Key Benefits

• Effective reduction of blood glucose levels

• Once-weekly dosing improves treatment adherence

• Low risk of hypoglycemia when used alone

• Supports gradual weight reduction

• Proven efficacy and safety profile in type 2 diabetes management

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis

• Use with caution in patients with a history of pancreatitis

• Not recommended in patients with a personal or family history of medullary thyroid carcinoma

• Gastrointestinal symptoms are common during dose initiation and escalation

• Regular monitoring of blood glucose is advised

Adverse Effects

Commonly reported adverse effects may include:

• Nausea and vomiting

• Diarrhea or constipation

• Abdominal discomfort

• Decreased appetite

• Injection site reactions

Most side effects are mild to moderate and tend to decrease with continued use.

Storage Conditions

Store Mylenda Injection in a refrigerator at 2°C–8°C. Do not freeze. Protect from light. After first use, follow storage instructions provided by the manufacturer. Keep out of reach of children.

Conclusion

Mylenda Injection 0.25 mg/0.5 ml (Semaglutide) is a modern, effective injectable therapy for type 2 diabetes mellitus. With its once-weekly dosing, multifaceted glucose-lowering mechanism, and added benefit of weight reduction, it offers a convenient and reliable option for long-term diabetes management under medical supervision.